Allogeneic cell therapy hasn’t caught up to autologous cell therapy yet, and the disappointing data so far has soured the entire allogeneic field for at least one venture capitalist. The cell therapy debate was one of the topics covered during a panel discussion at the Biopharm America conference.
Kineticos Ventures has been busy investing as well. In late May, eXmoor pharma, a UK cell and gene therapy manufacturer partner closed on a $35 million Series A round of funding from Kineticos and one other.
Pharmaceutical manufacturer Kincell Bio has recently received a significant investment of US$36 million in stealth funding, led by Kineticos Ventures. Kincell Bio specializes in engineering cells into advanced therapies and is known for manufacturing commercially viable immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programmes.
Kincell Bio, a new company formed to develop and manufacture cell therapies for biotechnology companies, may be based in Florida, but it has North Carolina fingerprints all over it. And also management has lots of new cash.